Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8976911 | 1.00 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL5486969 | 1.00 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL18224217 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL16485550 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL11239042 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL13588070 | 0.95 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL19065177 | 0.95 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL27829774 | 0.95 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL8583909 | 0.94 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL8583904 | 0.93 | CTSL (0.49) | CTSLCTSBCTSSCTSKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527418-B | Preparation method of ADC linker | 成都普康唯新生物科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113527418-A | Preparation method of ADC linker | 成都普赛唯新生物科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20190276389-A1 | SYNTHESIS OF ARYL CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY | 2019-09-12 | — | — | US | disclosed |
| US-20190276389-A1 | SYNTHESIS OF ARYL CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY | 2019-09-12 | — | — | US | disclosed |
| EP-3390352-A1 | SYNTHESIS OF CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | The Procter and Gamble Company (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106279-A1 | SYNTHESIS OF CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-8318798-B2 | Therapeutic agent for neurodegenerative disease | NATIONAL UNIVERSITY CORPORATION HOKKALDO UNIVERSITY (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2407167-A2 | Therapeutic agent for neurodegenerative disease | National University Corporation Hokkaido University (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20090233872-A1 | Therapeutic Agent for Neurodegenerative Disease | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1974732-A1 | THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE | National University Corporation Hokkaido University (JP) | 2008-10-01 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| US-4719312-A | FLUOROALKYLAMINES | MERCK & CO., INC. (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4459225-A | ANALGESICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-07-10 | — | — | US | disclosed |
| EP-0024664-B1 | PEPTIDE AMIDES AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4350628-A | OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE | RESEARCH CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4283328-A | TREATING AN N-BLOCKED AMINO ACID RESIDUE WITH A TETRAMETHYL GUANIDINIUM SALT OF A PEPTIDE CHAIN | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4261884-A | DESIRABLE BIOLOGICAL PROPERTIES AND STABILITY TO ENZYME CLEAVAGE | RESEARCH CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0024664-A1 | Peptide amides and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-03-11 | — | — | EP | disclosed |
| EP-0010830-A2 | Dehydropeptides | Research Corporation (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276389-A1 | SYNTHESIS OF ARYL CYCLOHEXANE ESTER DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | CUTA, TAS2R8, TRPA1 | CTSL 3705/4885CTSB 3333/4885CTSS 1037/4885 |
| US-20090233872-A1 | Therapeutic Agent for Neurodegenerative Disease | PARK7, HSPD1, FASTKD1 | CTSL 2308/4885CTSB 1760/4885CTSS 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.